Cynomolgus and rhesus macaques are both used in preclinical research, but neither is the right choice for every program. The decision follows the study question: whether the candidate is pharmacologically active in the species, whether the model reflects the relevant disease biology, and whether the planned endpoints inform the next development decision.
Prisys Biotech's NHP research is primarily centered on cynomolgus macaque models. If you are comparing species for a specific program, discuss model fit and study scope with the Prisys team. A brief, non-confidential outline is enough to start.
At a glance: the right species depends on the question
| Decision factor | What to establish before selecting a species |
|---|---|
| Target pharmacology | Does the candidate bind and activate or inhibit the target in the species? Is functional activity demonstrated in the relevant tissue or cell system? |
| Modality and delivery | Could species-specific receptors, vector tropism, route of administration, or anatomy affect exposure or interpretation? |
| Disease biology | Does the proposed model reproduce the mechanism and features relevant to the program, rather than only a surface-level phenotype? |
| Endpoints | Can the selected species support the required PK/PD, biomarker, imaging, behavioral, pathology, or functional measurements? |
| Prior evidence | Are there relevant data for the same species, population, model, modality, and endpoint, and are the study conditions comparable? |
| Feasibility and welfare | Can the study be conducted with appropriate sourcing, veterinary care, procedures, approvals, and a justified use of animals? |
A species label alone does not establish translational relevance. The candidate, target, model, study design, and evidence package must be considered together.
What is the difference between cynomolgus and rhesus macaques?
Cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta) are distinct macaque species. Both are used in biomedical research, and both carry meaningful genetic variation among individuals and populations. Cynomolgus and rhesus should not be treated as uniform biological profiles that predict how every candidate will behave.
A comparative genome study reported genetic differences among cynomolgus macaques, Chinese rhesus macaques, and Indian rhesus macaques, and identified evidence consistent with historical gene flow between some populations. That work is useful context for macaque diversity; it does not settle which species suits a particular drug, target, or disease model. Yan et al., Nature Biotechnology (2011).
The practical comparison for study planning is narrower than a list of species-wide advantages: whether the proposed animals and study system answer the specific question with interpretable data.
How to select a species for a preclinical program
1. Confirm pharmacological relevance for the candidate
For a biologic or other species-selective modality, begin with the target. Compare the relevant target sequence and binding characteristics, then assess functional activity in an appropriate assay. Binding alone does not establish the desired biological activity. Small molecules, oligonucleotides, and gene therapies each demand different checks: evaluate the candidate's mechanism, tissue exposure, and species-dependent biology instead of assuming that one macaque species is broadly preferable.
If neither species provides relevant pharmacology for the question, a macaque study will not answer it. Weigh the available alternative systems and the overall evidence strategy before committing to an NHP study.
2. Match the model to the mechanism and decision
Ask what decision the study must support: proof of concept, target engagement, exposure-response, a delivery question, a functional readout, or a selected safety assessment. Then check whether the model's induction method, disease features, time course, and endpoints align with that decision. A model name or an apparent resemblance to a human condition is not enough; its limitations belong next to its intended use.
3. Select endpoints that can be interpreted together
A single study often combines clinical observations, laboratory biomarkers, PK/PD, imaging, behavior, electrophysiology, or histopathology, provided the protocol supports an integrated interpretation. Each endpoint needs a defined role. An imaging signal, for example, shows the distribution of a label under specified conditions; it does not by itself establish intact-drug exposure or pharmacological effect. The selected species must support both the measurement and the intended interpretation.
4. Separate pharmacology questions from safety-study requirements
A species used for a pharmacology or efficacy question is not automatically the appropriate species for a toxicology study. For biotechnology-derived pharmaceuticals, ICH S6(R1) addresses the selection of relevant species in relation to pharmacological activity and the product's characteristics. The applicable nonclinical strategy depends on the candidate and the development context, so species selection must be justified for the specific program rather than inferred from a general ranking of macaque species. For the framework itself, see the FDA's S6(R1) guidance page.
5. Check the evidence and operational fit
Review whether prior evidence matches the proposed species, population, model, modality, route, and endpoints. Confirm practical factors as well: animal availability, study duration, procedures, sample collection, imaging access, and welfare requirements. Body weight alone does not determine study cost or compound use. Dose basis, group design, route, formulation, sampling, and the full protocol all matter.
Cynomolgus or rhesus: a practical decision matrix
| If the program needs to... | Compare... | Avoid assuming... |
|---|---|---|
| Evaluate a biologic or immune-modulating candidate | Target binding, functional activity, relevant pathway biology, and any population-dependent variation | That either species is automatically cross-reactive or immunologically representative |
| Assess a disease-model response | Model mechanism, induction method, phenotype, time course, and endpoint history | That a model with a familiar disease label is validated for every mechanism |
| Study CNS function or delivery | Relevant anatomy, procedure feasibility, imaging or behavioral readouts, and evidence for the selected setup | That rhesus is inherently superior for all neuroscience, or that imaging proves intact therapeutic exposure |
| Plan PK/PD or exposure-response work | Assay suitability, sampling plan, target-mediated disposition, and exposure interpretation | That species differences can be predicted from body size alone |
| Plan a safety assessment | Candidate-specific pharmacological relevance and the applicable nonclinical framework |
That one species is universally preferred or that an NHP is always required |
How Prisys can support an NHP study discussion
Prisys Biotech conducts NHP preclinical research from AAALAC-accredited facilities, with a primary focus on cynomolgus macaque models. Its public NHP disease-model directory and NHP pharmacology overview describe the disease models and translational research capabilities available for a program. Those capabilities draw on clinical imaging, MRI-guided intracranial delivery, and AI-based behavioral analysis. Confirm the availability of a particular species, model, assay, and procedure for each program before a protocol is planned.
For an initial discussion, share the information that can be provided without disclosing confidential details:
- therapeutic area and development stage;
- modality and target or mechanism, if shareable;
- the decision the study needs to inform;
- the species or model under consideration and why;
- essential endpoints, procedures, imaging, or sampling needs; and
- anticipated timing or other study constraints.
This gives the team a basis to discuss model fit, endpoint strategy, and the information needed for a scoped proposal. Please do not send confidential sequences, compound structures, or complete proprietary protocols through an unsecured channel.
Discuss your NHP study requirements with Prisys Biotechnologies: email the business-development team or reach the team through the contact page.
Frequently asked questions
Q: Are cynomolgus monkeys better than rhesus monkeys for preclinical research?
A: Neither species is universally better. Select on candidate-specific pharmacology, model fit, endpoints, relevant prior evidence, and study feasibility. The answer can differ between programs using the same modality.
Q: Which species should be used for a monoclonal antibody study?
A: First determine whether the antibody binds and produces the intended functional activity against the target in the proposed species. Then assess target distribution, model relevance, endpoints, and the purpose of the study. Do not select a species based on a general rule about macaques.
Q: Are rhesus monkeys preferred for neuroscience studies?
A: Not as a blanket rule. The relevant question is whether the chosen species and model support the particular neuroscience endpoint, procedure, and interpretation. Check historical evidence for comparability to the proposed study.
Q: Does a smaller cynomolgus macaque require less study compound?
A: Not necessarily. Compound use depends on the dose basis, study design, route, formulation, sampling plan, and other protocol requirements. Body size alone is not a reliable basis for estimating total compound needs.
Q: Does every preclinical safety program require an NHP study?
A: No. Whether an NHP study is appropriate depends on the product, the scientific question, available alternatives, and the applicable development framework. A program-specific assessment is needed.
Q: Can Prisys support a rhesus macaque study?
A: Prisys' NHP research is primarily centered on cynomolgus macaque models. Contact the team to confirm whether a particular rhesus-based program, model, or study scope can be supported.
